Synonyms: IMP-4297 | IMP4297
Compound class:
Synthetic organic
Comment: Senaparib (IMP4297) is an oral PARP1 inhibitor that is being developed in a joint venture between IMPACT Therapeutics and Junshi Biosciences, for the treatment of BRCA-mutated solid tumours. It is one of the chemical structures claimed in patent WO2012130166A1 [1].
|
|
Classification | |
Compound class | Synthetic organic |
IUPAC Name |
5-fluoro-1-[[4-fluoro-3-(4-pyrimidin-2-ylpiperazine-1-carbonyl)phenyl]methyl]quinazoline-2,4-dione |
International Nonproprietary Names | |
INN number | INN |
11260 | senaparib |
Synonyms |
IMP-4297 | IMP4297 |
Database Links | |
CAS Registry No. | 1401682-78-7 (source: WHO INN record) |
GtoPdb PubChem SID | 434122259 |
PubChem CID | 68389008 |
Search Google for chemical match using the InChIKey | VBTUJTGLLREMNW-UHFFFAOYSA-N |
Search Google for chemicals with the same backbone | VBTUJTGLLREMNW |
Search PubMed clinical trials | senaparib |
Search PubMed titles | senaparib |
Search PubMed titles/abstracts | senaparib |
UniChem Compound Search for chemical match using the InChIKey | VBTUJTGLLREMNW-UHFFFAOYSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | VBTUJTGLLREMNW-UHFFFAOYSA-N |